Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Oppenheimer boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) from $55 to $59. Oppenheimer analyst Francois Brisebois reiterated an Outperform rating. Tarsus Pharmaceuticals shares gained 18.3% to close at $39.22 on Tuesday. See how other analysts view this stock.
- Wedbush increased the price target for Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) from $60 to $67. Wedbush analyst Laura Chico maintained a Neutral rating. Apellis Pharmaceuticals shares fell 3.3% to close at $69.35 on Tuesday. See how other analysts view this stock.
- Needham increased Axon Enterprise, Inc. (NASDAQ: AXON) price target from $240 to $315. Needham analyst Joshua Reilly maintained a Buy rating. Axon Enterprise shares rose 0.1% to close at $271.82 on Tuesday. See how other analysts view this stock.
- Mizuho slashed the price target for Essex Property Trust, Inc. ...